Are Compounded GLP-1 Safe? Understanding the Risks and Benefits

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compounded GLP-1 preparations are not FDA-approved, and the honest answer to "are they safe" begins there. The FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness or quality before they are marketed. That does not make them unlawful or illegitimate — 503A compounding is a long-standing part of pharmacy practice — but it does mean the safety assurance comes from state pharmacy oversight and the individual pharmacy's own controls rather than from a federal premarket review. The specific risks are documented, and worth knowing precisely.

What the FDA Has Actually Recorded

As of May 31, 2026 the agency reported receiving 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. It notes that federal law does not require state-licensed pharmacies which are not outsourcing facilities to submit adverse event reports, so these figures are likely undercounts.

Many of the reported events appear consistent with adverse events seen with the FDA-approved versions — that is, the gastrointestinal profile familiar from the labels rather than a distinct signal.

The agency is also candid that it is not always possible to determine whether an adverse event resulted directly from the drug or from other factors. That uncertainty cuts both ways and is worth stating plainly.

Dosing Error Is the Distinct Risk of This Category

The FDA has received multiple reports of adverse events, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide. These arose from patients measuring and self-administering incorrect doses, and in some cases from clinicians miscalculating doses.

A separate set of reports may relate to patients being prescribed compounded semaglutide or tirzepatide in doses beyond what appears in the FDA-approved label — more product in a single dose, more frequent dosing, or faster escalation. Reported symptoms included nausea, vomiting, diarrhea, abdominal pain and constipation, some serious enough to prompt medical attention.

This is a category-specific hazard. Approved products ship in fixed presentations with FDA-reviewed instructions for use; a compounded vial may require measurement, which introduces a step that can go wrong. The FDA encourages patients to discuss measurement and administration directly with their prescriber or compounder.

Ingredient and Sourcing Risks

Salt forms are the clearest example. The agency states that semaglutide sodium and semaglutide acetate are different active ingredients from the one used in the approved drugs, that it lacks information on whether they share the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding.

Retatrutide and cagrilintide cannot be used in compounding under federal law. They are not components of FDA-approved drugs and have not been found safe and effective for any condition. The FDA has warned telehealth companies, active pharmaceutical ingredient distributors and outsourcing facilities in connection with them.

The agency has established an import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns. It operates as a green list, exempting API from manufacturers that appear compliant on inspection, and it does not create new limits on lawful compounding.

Fraud and Handling Failures

The FDA is aware of fraudulent compounded semaglutide and tirzepatide carrying false label information — labels naming pharmacies that did not compound the product, and in some cases pharmacies that do not exist. One reported adverse event involved a product labeled as compounded tirzepatide from a pharmacy that had not compounded it, with redness, swelling, pain and a lump at the injection site.

Cold chain is a separate failure mode. Injectable GLP-1 drugs require refrigeration as stated in their package inserts, and the agency has received complaints of compounded GLP-1 drugs arriving warm or with inadequate ice packs. Its recommendation is not to use any injectable GLP-1 drug that arrives warm or insufficiently refrigerated.

Counterfeits of approved products exist too. The FDA has warned about counterfeit Ozempic in the U.S. market and about illegally marketed semaglutide and tirzepatide sold online, including products falsely labeled "for research purposes" or "not for human consumption" but sold to consumers with dosing instructions.

What Reduces Risk in Practice

A genuine prescription from a licensed clinician who has evaluated you, filled at a state-licensed pharmacy, is the FDA's own baseline recommendation. Everything outside that is higher risk by construction.

Knowing which pharmacy compounded your preparation, that it is licensed in your state, that the base form rather than a salt form was used, and what potency and sterility testing was performed are all reasonable things to ask and to receive answers to.

PlexusDx works only with licensed 503A compounding pharmacies. That is a meaningful constraint rather than a slogan, because the 503A framework is what makes patient-specific compounding lawful in the first place.

Warning Signs the FDA Publishes for Consumers

Claims that a compounded drug is the same as an FDA-approved drug. Deep discounts or prices that seem too good to be true. Medicine that looks different from what you previously received, or that arrives in broken or damaged packaging or without instructions for use.

No screening and prescription by a licensed clinician before medicine is provided. No licensed clinician available to answer questions after you receive it. Spelling errors on the label, incorrect pharmacy addresses, or a pharmacy name you suspect may be fraudulent.

Any of these is a reason to stop and verify rather than to proceed. The agency publishes them precisely because this market has attracted actors operating outside the framework.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Are compounded GLP-1 medications FDA-approved?

No. The FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness or quality before they are marketed. They are prepared by state-licensed pharmacies against prescriptions for individual patients under section 503A, with state boards of pharmacy as the primary regulator. They are also not generic versions of any approved brand.

How many adverse events have been reported?

As of May 31, 2026 the FDA reported 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency notes that federal law does not require state-licensed pharmacies which are not outsourcing facilities to submit adverse event reports, so it considers these figures likely to understate the true number.

What is the most common specific risk?

Dosing error. The FDA has received multiple reports of adverse events, some requiring hospitalization, that may relate to patients measuring and self-administering incorrect doses of compounded injectable semaglutide, and in some cases to clinicians miscalculating doses. A separate set relates to prescribing beyond the doses in the approved label — larger single doses or faster escalation.

How do I know my compounded medication is legitimate?

Confirm that a licensed clinician evaluated you and wrote the prescription, that a state-licensed pharmacy is dispensing it, which pharmacy compounded it, that the base form rather than a salt form was used, and what testing was performed. Treat damaged packaging, missing instructions for use, label spelling errors or an incorrect pharmacy address as reasons to stop and verify.

What should I do if my shipment arrives warm?

Do not use it, and contact the dispensing pharmacy. Injectable GLP-1 drugs require refrigeration as stated in their package inserts, and the FDA has received complaints that compounded GLP-1 drugs arrived warm or with inadequate ice packs. The agency specifically recommends that patients not use any injectable GLP-1 drug that arrives warm or insufficiently refrigerated.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.